Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Cancer Immunol Res. 2021 Feb 22;9(5):583–597. doi: 10.1158/2326-6066.CIR-20-0427

Figure 3. Tumor-derived factor(s), including IL12, upregulate CD49a.

Figure 3.

(A) Thy1.1+CD8+ OT-I cells were activated with CD3/CD28 beads for 48 hours in the presence of IL2 and IL7, cultured for 3 additional days with IL2 and IL7, and then for 24 hours with BRPKp110-derived tumor lysate. CD49a expression was determined by flow cytometry. (B-D) CD8+ splenocytes were activated and cultured as in (A), and then for 24 hours with (B) BRPKp110 culture lysate (BRPKp110-C), or lysates from B16-OVA or BRPKp110 tumors (BRPKp110-T); (C) the indicated cytokines; or (D) BRPKp110 tumor lysate with or without IL12 blocking antibody (aIL-12). Groups were compared with (A) a Welch’s corrected T-test or (B, D) one-way ANOVA. Bar graphs and error bars indicate mean +/− SD. Factors of significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.